| DC42425 |
Syk-IN-4
|
Syk-IN-4 is a potent, selective and orally bioavailable SYK with an IC50 of 0.31 nM. SYK has emerged as a potential target for autoimmunity and hematological cancers. |
| DC42007 |
Syk Kinase Peptide Substrate
|
Syk Kinase Peptide Substrate is a Syk kinase peptide substrate. |
| DC42006 |
Syk Kinase Peptide Substrate, Biotin labeled
|
Syk Kinase Peptide Substrate, Biotin labeled is a biotin-labled Syk kinase peptide substrate. |
| DC41092 |
Cerdulatinib hydrochloride
|
Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC50s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies. |
| DC40367 |
Syk-IN-1
|
Syk-IN-1 (compound 4) is a potent Syk inhibitor, with an IC50 of 35 nM. |
| DC28255 |
Lanraplenib succinate
|
Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans. |
| DC28254 |
Lanraplenib monosuccinate
|
Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans. |
